NAD+ Oral Supplement Pilot Intervention in Adult Females | NCT06579209 | Trialant

NAD+ Oral Supplement Pilot Intervention in Adult Females | NCT06579209 | Trialant

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
Pre-testing prior to intervention	No Intervention	Prior to receiving the supplement, either Nicotinamide adenine dinucleotide or the placebo, participants will undergo cognitive testing and a blood draw.
Post-testing after intervention	No Intervention	After receiving the supplement, either Nicotinamide adenine dinucleotide or the placebo, participants will undergo cognitive testing and a blood draw.
Intervention	Experimental	For four weeks, the participant will consume an oral supplement, either Nicotinamide adenine dinucleotide or a placebo.	Dietary Supplement: Treatment Other: Placebo

Interventions

Name	Type	Description	Arm Group Labels	Other Names
Treatment	Dietary Supplement	Participants will take a supplement for four weeks. The supplement will either be Nicotinamide adenine dinucleotide or a placebo.	Intervention

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Neurocognition	NIH Toolkit Cognition Battery, Automated Neuropsychological Assessment Metrics	four weeks
Neurodegenerative disease panel	BDNF, Cathespin D, MPO, PAI-1 (total), PDGF-AA, PDGF-AB/BB, RANTES, slCAM-1, sNCAM, sVCAM-1	four weeks
Markers of systemic inflammation	GM-CSF, IFNγ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70, IL-13, IL-17A, IL-23, TNFα	four weeks

Contacts/Locations Module

Condition Browse Module

Intervention Browse Module